Navigation Links
Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
Date:6/24/2008

SOUTH SAN FRANCISCO, Calif., June 24 /PRNewswire/ -- Portola Pharmaceuticals, a clinical-stage biopharmaceutical developing best-in-class therapeutics for acute and chronic cardiovascular and inflammatory diseases, today announced that Bill Lis has joined the company as Vice President of Business and Commercial Development. Mr. Lis will be responsible for the company's corporate partnering activities as well as commercial strategy for Portola's portfolio of clinical and preclinical programs. He will join the company's executive management team.

Mr. Lis has over 17 years of experience in biopharmaceutical and medical device sales & marketing, medical affairs, and business development. From 2005 until 2008 he was Vice President, Business and New Product Development, Scios, Inc. (A Johnson and Johnson Company) where, most recently, he was responsible for cardiovascular business licensing strategies and activities and commercial operations. He led successful in-licensing activities and pre-market and commercial infrastructure development for Xarelto(R) (rivaroxaban) a Phase III drug candidate, filed for EMEA regulatory approval. Prior to joining Scios, he was Director of Marketing and New Products, Millennium Pharmaceuticals, Inc. where he held positions of increasing leadership, including the management of marketing activities for Integrilin(R) (eptifibatide), a best in class antithrombotic drug. Previously, at Rhone Poulenc Rorer and Ethicon Endo Surgery he was involved in the launch and commercialization of several products, including Lovenox(R) (enoxaparin). He holds a B.S. in Finance from the University of Maryland.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular disease. Portola has two antithrombotic drug candidates in Phase II clinical development. Portola's lead compound, betrixaban (PRT054021), is an oral Factor Xa inhibitor with target markets that include the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction (MI) and stroke. Portola's other clinical compound, PRT060128, is an oral and intravenous ADP receptor antagonist being developed for patients with acute coronary syndrome, for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention and for secondary prevention of MI and stroke. In addition, Portola has a robust preclinical pipeline targeting opportunities in thrombosis and hemostasis as well as in cancer and inflammatory diseases.


'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series will ... American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates ... of how to continue to feed a growing nation. At the same time, many ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the ... and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
Breaking Biology News(10 mins):